2022-RA-822-ESGO Risk reducing surgery in ovarian cancer. (20th October 2022)

• Record Type: Journal Article
• Authors: Loizzi, Vera; Arezzo, Francesca; Romagno, Isabella; Dellino, Miriam; Silvestris, Erica; Kardhashi, Anila; Cazzato, Gerardo; Resta, Leonardo; Legge, Francesco; Damiani, Luca; Natalicchio, Iole; Resta, Nicoletta; Cicinelli, Ettore; Cormio, Gennaro
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A266
• Page End: A267
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.569
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: The study evaluated the risk of ovarian cancer in women with BRCA 1–2 mutations. BRCA 1–2 are tumor-suppressor genes involved in DNA homologous recombination and ovarian cancer development Methodology: From 2016 to may 2022, all risk reducing surgery (RRSO) which included salpingo-oophorectomy was performed in all patients carrying BRCA1 and BRCA 2 mutation. Results: We collected 172 women. The median age of BRCA 1 mutated patients was 51 aged (range 30–73 years), whereas the median age of BRCA 2 mutated patients was 53 (range 36–70). One hundred and three patients had previous history of breast cancer. Among the 172, 145 (85%) underwent risk reducing salpingo-oohorectomy (RRSO) though a laparoscopic minimally invasive approach. 12 (7%) underwent laparoscopic RRSO and contextual hysterectomy, 3 (2%) underwent RRSO through a laparotomic approach and 10 (6%) laparotomic RRSO and hysterectomy. During 8 (5%) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complications occurred in 3 patients (2%). Four patients (2%) were found to have occult serous tubal intraepithelial carcinoma (STIC) and nine patients (5%) occult cancer. Conclusion: RRSO is a safe and feasible procedure in BRCA 1–2 mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.